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Abstract
Purpose This study reports a case of bilateral rifabutin-
associated uveitis in a child with a history of acute myeloid
leukemia.
Methods We utilized a clinical case description and brief
discussion.
Results A 17-year-old girl presented with acute bilateral an-
terior uveitis, a hypopyon in the left eye, and moderate bilat-
eral vitritis. She had a history of acute myeloid leukemia status
post-allogeneic hematopoietic stem cell transplant 5 years
earlier. She was receiving rifabutin for a biopsy-proven My-
cobacterium avium complex pulmonary infection. Work up
for infectious and neoplastic etiologies was negative. The
uveitis initially responded to topical corticosteroids, but re-
curred when the drops were tapered. Fluorescein angiography
demonstrated diffuse vasculitis of small retinal vessels and
cystoid macular edema. After rifabutin was discontinued, the
uveitis and vasculitis slowly resolved.
Conclusion Fluorescein angiography demonstrated wide-
spread retinal vasculitis which is a rare manifestation of
rifabutin-associated uveitis.
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Introduction
Rifabutin is a semisynthetic derivative of rifampin that is
effective for the prophylaxis and treatment of Mycobacte-
rium avium complex (MAC) infection. It is frequently
used in immunocompromised patients with human immu-
nodeficiency virus (HIV) or a history of organ or stem
cell transplantation. Anterior uveitis and hypopyon are
well-recognized and frequently reported complications of
rifabutin treatment; however, posterior involvement is rel-
atively rare [1, 2]. Here, we describe a case of rifabutin-
associated panuveitis in a young patient with a history of
acute myeloid leukemia.
Case report
A 17-year-old Eritrean girl presented with a 5-day history of
redness, tearing, and photophobia which started in her right
eye (OD) and then involved her left (OS). She recalled
similar, but less severe symptoms over the 2 months prior
to presentation. Her medical history was significant for
acute myeloid leukemia diagnosed 5 years earlier. She was
treated with chemotherapy and received an allogeneic he-
matopoietic stem cell transplant 6 months after diagnosis.
She developed graft-versus-host-disease (GVHD) of the
gastrointestinal tract, lungs, and skin with mild ocular sur-
face involvement, but these issues were stable at the time of
presentation to the eye clinic.
On initial examination, pinhole visual acuity was 20/32
in each eye (OU), and intraocular pressures were 14 mmHg
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OU. Small non-granulomatous keratic precipitates were
present OU. The anterior chambers had 3+ and 4+ cells
(OD and OS, respectively), and bilateral moderate vitritis
was noted. The left eye also had a hypopyon (less than
1 mm) and posterior synechiae of the iris (Fig. 1). Both eyes
were treated with topical prednisolone acetate 1% every
hour and cyclopentolate twice daily. Due to the concern
for recurrent leukemia or infection, aqueous humor was
obtained from the left eye; cytology was negative for ma-
lignant cells, and cultures were negative. Laboratory testing
was negative or within normal limits for RPR, syphilis IgG,
hepatitis B and C, angiotensin-converting enzyme, lyso-
zyme, ANA, anti-dsDNA, rheumatoid factor, and HLA-
B27. The uveitis resolved after 2 weeks of intensive topical
corticosteroids.
Topical corticosteroids were tapered to every 2 hours
OU. Ten days later, the patient developed recurrent
bilateral anterior uveitis and vitritis with a hypopyon
OS. Fluorescein angiography (FA) showed diffuse reti-
nal vascular leakage and late staining of the optic
nerves in both eyes (Fig. 2a, b). A more detailed
review of her medications and medical history revealed
she was on rifabutin for recurrent MAC. Nearly 2 years
before she developed uveitis, she had completed a 9-
month course of ethambutol, clarithromycin, and rifa-
butin for MAC cultured from a lung biopsy. During the
same period, she was on systemic immunosuppressive
medications (mycophenolate mofetil, cyclosporine, and
prednisone) for GVHD. Eight months before presenting
with hypopyon uveitis, ethambutol, clarithromycin, and
rifabutin were restarted for recurrent MAC. Rifabutin
dosing was twice as high (300 mg every Monday,
Wednesday, and Friday), and she was no longer on
systemic immunosuppressive agents. After rifabutin-
associated uveitis was diagnosed, her medication was
switched from rifabutin to moxifloxacin. Topical corti-
costeroids were continued at the same frequency (every
2 hours), and the hypopyon resolved 5 days later. In
the first 2 weeks of follow-up, the macular edema
initially worsened, OS > OD, but over time, the thick-
ening gradually returned to normal (Fig. 3). On fluorescein
angiography, the diffuse retinal leakage had improved at
5 weeks and had resolved after 4 months on a slow topical
corticosteroid taper (Fig. 2c–f).
Discussion
Anterior uveitis and hypopyon are the most frequent mani-
festations of rifabutin-associated uveitis; however, severe
cases may develop dense vitritis with large yellow-white
opacities or panuveitis resembling endophthalmitis [3, 4].
Despite the strong association with rifabutin, infectious,
autoimmune and neoplastic etiologies should still be inves-
tigated depending on the clinical situation. Examination of
aqueous humor and/or vitreous via culture, cytology, or
polymerase chain reaction can help rule out infection or
malignancy.
Although mild to moderate vitritis frequently devel-
ops in rifabutin-associated uveitis, posterior involvement
is less frequent [5–7]. Similar to the previous cases, our
patient presented with uveitis several months after the
start of rifabutin and responded quickly to topical cor-
ticosteroids and discontinuation of rifabutin. Of the four
cases described by Skolik, only one patient had diffuse
vasculitis on FA; the others had mild peripheral vascu-
litis or perivascular sheathing. Of note, the patient with
diffuse FA changes was immunocompetent, whereas the
other patients had acquired immunodeficiency disease
syndrome (AIDS) and CD4 counts less than 100 cells/
mm3. In each of the single case reports by Arevalo and
Vaudaux, the rifabutin-associated uveitis was unilateral
and the posterior findings were focal. Arevalo’s patient
had AIDS and a CD4 count of 3 cells/mm3; a focal area
of sclerosed retinal vessels was noted after intraocular
injections of vancomycin and gentamicin for presumed
endophthalmitis. In the case from Vaudaux, the patient
had been treated with systemic prednisone for chronic
obstructive pulmonary disease 4 months prior to devel-
oping uveitis, but was otherwise immunocompetent. The
FA and ocular coherence tomography (OCT) confirmed
unilateral cystoid macular edema. In our immunocom-
petent patient, the vasculitis was notable for its diffuse
and bilateral nature and slow resolution after the dis-
continuation of rifabutin.
Rifabutin-associated uveitis was initially described in
HIV-positive patients, but it may also occur in patients
who are immunocompetent [7]. Only a few pediatric
cases have been reported [8]; however, due to the possi-
ble association with low body weight [2], weight-based
dosing has been suggested as a strategy to prevent
Fig. 1 Anterior segment photograph of the left eye showing a small
hypopyon and visible vitreous debris (posterior synechiae were broken
by dilation)
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Fig. 2 Fluorescein
angiography montages of the
right and left eyes: a, b Baseline
(prior to discontinuation of
rifabutin). c, d Five weeks after
stopping rifabutin. e, f Four
months after stopping rifabutin
Fig. 3 Cirrus OCT of the left
eye: Cystoid macular edema
present 9 days (a) after stopping
rifabutin that resolved 1 month
later (b)
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uveitic complications. Our patient weighed 42.5 kg, and
uveitis developed after the rifabutin was restarted at twice
the initial dose. It is unclear whether the lack of systemic
immunomodulatory medications influenced the onset of
uveitis during the second course of rifabutin since patients
have developed rifabutin uveitis while iatrogenically immu-
nosuppressed after transplantation [9]. Perhaps an intact
immune system predisposed our patient to develop more
extensive retinal vasculitic changes.
Conclusion
We describe a case of rifabutin-associated hypopyon uveitis
in a young immunocompetent patient with an unusual de-
gree of diffuse bilateral retinal vasculitis. While the anterior
chamber and vitreous inflammation disappeared rapidly af-
ter discontinuation of rifabutin, resolution of the retinal
vasculitis took several months. Fluorescein angiography
helped assess the extent and severity of uveitis as well as
guide the topical corticosteroid taper.
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